Cargando…
Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dysregulates the immune system by lymphopenia of B cells, monocytes, eosinophils, basophils, and cytotoxic cells such as CD8, γδ T cells, and natural killer (NK) cells. Despite many studies being conducted to better understand th...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228064/ https://www.ncbi.nlm.nih.gov/pubmed/34071430 http://dx.doi.org/10.3390/vaccines9060562 |
_version_ | 1783712654913699840 |
---|---|
author | Lo Presti, Elena Dieli, Francesco Meraviglia, Serena |
author_facet | Lo Presti, Elena Dieli, Francesco Meraviglia, Serena |
author_sort | Lo Presti, Elena |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dysregulates the immune system by lymphopenia of B cells, monocytes, eosinophils, basophils, and cytotoxic cells such as CD8, γδ T cells, and natural killer (NK) cells. Despite many studies being conducted to better understand the effects of SARS-CoV-2 on the immune system, many mechanisms still remain unclear, hindering the development of novel therapeutic approaches and strategies to improve the host’s immune defense. This mini-review summarizes the findings on the role of γδ T cells in coronavirus disease 2019 (COVID-19), providing an overview of the excellent anti-viral therapeutic potential of γδ T cells, that had not yet been exploited in depth. |
format | Online Article Text |
id | pubmed-8228064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82280642021-06-26 Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities Lo Presti, Elena Dieli, Francesco Meraviglia, Serena Vaccines (Basel) Perspective Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection dysregulates the immune system by lymphopenia of B cells, monocytes, eosinophils, basophils, and cytotoxic cells such as CD8, γδ T cells, and natural killer (NK) cells. Despite many studies being conducted to better understand the effects of SARS-CoV-2 on the immune system, many mechanisms still remain unclear, hindering the development of novel therapeutic approaches and strategies to improve the host’s immune defense. This mini-review summarizes the findings on the role of γδ T cells in coronavirus disease 2019 (COVID-19), providing an overview of the excellent anti-viral therapeutic potential of γδ T cells, that had not yet been exploited in depth. MDPI 2021-05-28 /pmc/articles/PMC8228064/ /pubmed/34071430 http://dx.doi.org/10.3390/vaccines9060562 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Perspective Lo Presti, Elena Dieli, Francesco Meraviglia, Serena Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities |
title | Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities |
title_full | Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities |
title_fullStr | Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities |
title_full_unstemmed | Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities |
title_short | Lymphopenia in COVID-19: γδ T Cells-Based Therapeutic Opportunities |
title_sort | lymphopenia in covid-19: γδ t cells-based therapeutic opportunities |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228064/ https://www.ncbi.nlm.nih.gov/pubmed/34071430 http://dx.doi.org/10.3390/vaccines9060562 |
work_keys_str_mv | AT loprestielena lymphopeniaincovid19gdtcellsbasedtherapeuticopportunities AT dielifrancesco lymphopeniaincovid19gdtcellsbasedtherapeuticopportunities AT meravigliaserena lymphopeniaincovid19gdtcellsbasedtherapeuticopportunities |